Ledipasvir

Summary

Ledipasvir (CHEMBL2374220) is an approved small-molecule antiviral drug; indicated across 6 conditions including hepatitis c virus infection and chronic hepatitis c virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 42
• Chemistry: 889 Da · C49H54F2N8O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2374220
Name	Ledipasvir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	67505836
ChEBI	CHEBI:85089
Molecular formula	C49H54F2N8O6
Molecular weight	889
InChIKey	VRTWBAAJJOHBQU-KMWAZVGDSA-N

SMILES: CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

IUPAC name: methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate

ChEBI definition: A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.

Pharmacological roles (ChEBI): antiviral drug, hepatitis C protease inhibitor.

Also known as: GS-5885, Ledipasvir, Ledipasvir acetonate, Ledipasvir component of harvoni, LEDIPASVIR, ledipasvir, LedipasvirÊ, LedipasvirÂ

Patent coverage: 579 distinct patent families (1,454 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 1,285 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hepatitis C virus infection	4	MONDO:0005231	EFO:0003047
chronic hepatitis C virus infection	4	MONDO:0005354	EFO:0004220

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
lymphoma	2	MONDO:0005062	EFO:0000574
hepatitis B virus infection	2	MONDO:0005344	EFO:0004197

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE2	14
PHASE4	9
PHASE3	7
Not specified	7
PHASE1	3
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02717949	PHASE4	TERMINATED	Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
NCT02768961	PHASE4	COMPLETED	Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)
NCT02959359	PHASE4	WITHDRAWN	DAA in the Risk of Recurrence After Curative Treatment of HCC
NCT02964091	PHASE4	COMPLETED	Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
NCT02992457	PHASE4	COMPLETED	Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
NCT03279133	PHASE4	WITHDRAWN	Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
NCT03721627	PHASE4	UNKNOWN	Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.
NCT04457050	PHASE4	COMPLETED	Effect of Hepatitis C Clearance on Insulin Resistance
NCT04498936	PHASE4	COMPLETED	Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19
NCT02555943	PHASE2/PHASE3	COMPLETED	DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
NCT02576314	PHASE3	COMPLETED	Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
NCT02597166	PHASE3	COMPLETED	Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
NCT02705534	PHASE3	COMPLETED	Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
NCT02771405	PHASE3	COMPLETED	Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
NCT03061032	PHASE3	UNKNOWN	Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients
NCT03343444	PHASE3	UNKNOWN	Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
NCT04353986	PHASE3	UNKNOWN	PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
NCT01353248	PHASE2	COMPLETED	GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
NCT01356160	PHASE2	COMPLETED	GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
NCT01371578	PHASE2	COMPLETED	Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
NCT01384383	PHASE2	TERMINATED	GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
NCT01434498	PHASE2	COMPLETED	GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
NCT01435226	PHASE2	COMPLETED	GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
NCT01805882	PHASE2	COMPLETED	Combination Therapy for Chronic Hepatitis C Infection
NCT02405013	PHASE2	COMPLETED	Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
NCT02421211	PHASE2	COMPLETED	A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
NCT02480387	PHASE2	COMPLETED	Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
NCT02605304	PHASE2	TERMINATED	12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
NCT02836925	PHASE2	COMPLETED	Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
NCT03261349	PHASE2	UNKNOWN	Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
NCT03312023	PHASE2	COMPLETED	Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
NCT03903185	PHASE1/PHASE2	COMPLETED	Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
NCT01193478	PHASE1	COMPLETED	A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
NCT02128217	PHASE1	COMPLETED	Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
NCT02683005	PHASE1	COMPLETED	Study of Hepatitis C Treatment During Pregnancy
NCT02333292	Not specified	COMPLETED	Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
NCT02510300	Not specified	TERMINATED	A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
NCT02657694	Not specified	UNKNOWN	Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods
NCT02758509	Not specified	COMPLETED	Impact of Antiviral Therapy on Gastroesophageal Varices.
NCT02760355	Not specified	COMPLETED	Extrahepatic Insulin Resistance in Chronic Hepatitis C
NCT03169348	Not specified	UNKNOWN	The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia
NCT04047680	Not specified	COMPLETED	eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 4 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).